The resulting dramatic morphologic and molecular changes, such as the E-cadherin loss that is commonly seen in the clinic36, indicates that our new ccRCC model is more similar and applicable to clinical disease. This evidence concerns the gene CDH1 and nonpapillary renal cell carcinoma.